近日,跨国药企礼来发布2024年财报。数据显示,公司去年全年营收450.43亿美元,同比增长32%;净利润105.9亿美元,同比增长106%。其中GIPR/GLP-1R双重激动剂替尔泊肽(包括减重版和降糖版)销量大增,合计销售额达164.66亿美元,在总收入中占比超36%。展望2025年,礼来预计全年营收将达到580亿至610亿美元。GLP-1“带飞”第四季度业绩单从第四季度数据来看,礼来实现营收...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.